Ladenburg lowered the firm’s price target on Bionano Genomics to $14 from $24 and keeps a Buy rating on the shares after the company announced Q4 and FY23 preliminary topline results. Based on the company’s commentary and the firm’s general 2024 outlook, it has reduced its FY24 and FY25 revenue forecasts, but says that with the granting of CPT codes, which could occur mid-year 2024, “topline growth could benefit materially.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BNGO:
- Bionano announces study results in support of establishing OGM as SOC
- Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
- Bionano Genomics announces 2024 Symposium
- Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
- Bionano Genomics sees FY23 revenue $35.8M-$36.1M, consensus $35.94M
